New drug combo aims to improve outcomes for elderly lymphoma patients

NCT ID NCT05245656

Recruiting now Disease control Sponsor: Kim, Seok Jin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests whether alternating two chemotherapy regimens (RB and RBAC) works better than the standard RB regimen alone for elderly patients newly diagnosed with mantle cell lymphoma who are not eligible for a stem cell transplant. About 90 participants will be randomly assigned to one of the two treatment groups. The study measures how long the cancer stays under control, overall survival, and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Rituximab, Bendamustine, and Cytarabine (chemotherapy drugs)
What this could lead to: If this works, it could offer a more effective first-line treatment option for elderly patients with mantle cell lymphoma who cannot undergo a stem cell transplant.
What could go wrong: This is a phase 2 trial with only 90 participants, so results are preliminary. Adding cytarabine may increase side effects, and the benefit over standard therapy is not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

Samsung Medical Center
RECRUITING

Seoul, Gangnam-Gu, 06351, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.